; and (B) with respect to the Department of Health and Human Services, not more than 15 percent of the total funds allocated to the SBIR and STTR programs of the Department of Health and Human Services during that fiscal year. (3) Extension During fiscal years 2024 and 2025, each Federal agency with an SBIR or STTR program may continue phase flexibility as described in this subsection only if— (A) the reports required under subsection (tt)(1)(B) have been submitted to the appropriate committees; (B) the results in the reports demonstrate that skipping Phase I is effective at commercializing SBIR and STTR projects; and (C) the allocation percentages in subsections (f)(1) and (n)(1) have been increased above 3.2 percent and .45 percent, respectively. ; (5) in subsection (hh)(2)(A)(i), by striking procedures and model contracts and inserting processes and requirements and simplified and standardized model contracts or awards ; and (6) by adding at the end the following: (vv) Technology Commercialization Official Each Federal agency participating in the SBIR or STTR program shall designate a Technology Commercialization Official in the Federal agency, who shall— (1) have sufficient commercialization experience; (2) provide assistance to SBIR and STTR program awardees in commercializing and transitioning technologies; (3) identify SBIR and STTR program technologies with sufficient technology and commercialization readiness to advance to Phase III awards or other non-SBIR or STTR program contracts; (4) coordinate with the Technology Commercialization Officials of other Federal agencies to identify additional markets and commercialization pathways for promising SBIR and STTR program technologies